Compounded vs research-grade vs FDA-approved

Three tiers, three frameworks

The same active peptide molecule can exist in three different regulatory states, with very different quality and access implications:

1. FDA-approved finished pharmaceutical product. Manufactured under cGMP by the FDA-approved manufacturer, with documented identity, purity, potency, and stability. Examples: Ozempic, Wegovy, Mounjaro, Zepbound, Forteo, Sandostatin, Vyleesi.
2. Compounded by a licensed pharmacy. Prepared by a 503A or 503B compounding pharmacy from active pharmaceutical ingredient. Quality varies by facility; the FDA does not pre-approve compounded products. Examples: compounded semaglutide, compounded tirzepatide (during shortage designation), compounded testosterone.
3. Research-grade ("research chemical") product. Sold by chemical suppliers with "for laboratory research only" labeling. No regulatory oversight as a drug. Quality, identity, and dose vary widely. Examples: most BPC-157, TB-500, MOTS-c, and other research-only peptides.

What's different across the tiers

Quality oversight

FDA-approved: cGMP manufacturing, FDA inspection · Compounded: state board oversight, FDA jurisdiction over outsourcing facilities (503B) · Research-grade: typically none

Identity verification

FDA-approved: confirmed · Compounded: depends on pharmacy, API source verification varies · Research-grade: rarely verified by user; supplier certificate of analysis varies in reliability

Dose accuracy

FDA-approved: pre-filled pen, defined dose · Compounded: vials with patient-measured doses (significant error risk) · Research-grade: vials, often with mislabeled concentration

Legal status (US)

FDA-approved: prescription drug · Compounded: legal when shortage-designated and prescribed · Research-grade: not legal for human use under current FDA framework

Cost

FDA-approved: highest (especially without insurance coverage) · Compounded: typically 3–10× cheaper · Research-grade: typically cheapest by absolute price, but per-unit varies

Adverse-event surveillance

FDA-approved: MedWatch and integrated pharmacovigilance · Compounded: state-level and FDA where outsourcing is involved · Research-grade: essentially none

What the FDA has specifically flagged

The 2023–2024 wave of FDA enforcement around compounded GLP-1s focused on three specific patterns:

• Salt-form substitutions. Some compounded products use semaglutide sodium or semaglutide acetate rather than the form used in approved Ozempic / Wegovy. The FDA's position is that these salt forms are different active ingredients, raising identity and efficacy questions.
• Hospitalizations from dosing errors. Adverse events from compounded GLP-1s have included dosing errors with vial-based products that don't have the pre-filled-pen guardrails of approved products.
• API source quality. The FDA has noted concerns about API sources used by some compounding pharmacies that have not been inspected to U.S. drug-manufacturing standards.

The research-grade marketplace

The research-grade category — peptides sold by chemical suppliers with "for laboratory research only" labeling — operates outside the FDA framework for human drugs. Use in humans is not a legal use case under the framework as written; the labeling is part of how the products avoid being treated as unapproved drugs.

For curious readers, the relevant practical considerations:

• Identity verification is the user's responsibility and is rarely actually performed.
• Quality varies dramatically across suppliers, and even within suppliers across batches.
• Adverse-event reporting is essentially nonexistent — meaning the safety database that ordinarily develops around a compound's use is absent.
• Compound identity at the molecular level (correct sequence, correct disulfide bridging, absence of degradation products) requires analytical capabilities most users don't have.

How to think about the choice

For any specific compound, the relevant questions are:

1. Is there an FDA-approved version? (For semaglutide, tirzepatide, PT-141, octreotide, teriparatide, desmopressin, and others — yes.)
2. If yes, what does access look like? (Cost, insurance, indication match.)
3. If FDA-approved isn't accessible, is the compound currently in an FDA shortage designation that supports legal compounding?
4. If no compounding pathway exists, the compound is research-grade only — and the considerations in the previous section apply.

The decision tree often produces different answers for different people and different compounds. Understanding the framework is more useful than a one-size-fits-all rule.